Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Peer-reviewed

Research Article

Association between dietary intake of flavonoid and chronic kidney disease in US adults: Evidence from NHANES 2007-2008, 2009-2010, and 2017-2018

  • Peijia Liu ,

    Contributed equally to this work with: Peijia Liu, Wujian Peng

    Roles Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Software

    Affiliation Department of Nephrology, Shenzhen Third People’s Hospital, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong, China

    ⨯
  • Wujian Peng ,

    Contributed equally to this work with: Peijia Liu, Wujian Peng

    Roles Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software

    Affiliation Department of Nephrology, Shenzhen Third People’s Hospital, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong, China

    ⨯
  • Feng Hu,

    Roles Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing

    Affiliation Department of Nephrology, Shenzhen Third People’s Hospital, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong, China

    ⨯
  • Guixia Li

    Roles Funding acquisition, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing

    liguixia120@163.com

    Affiliation Department of Nephrology, Shenzhen Third People’s Hospital, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong, China

    ⨯

Abstract

Background

Studies investigating the relationship between flavonoid intake and chronic kidney disease (CKD) are limited. This study investigated the association between daily flavonoid intake and CKD in US adults by using data for 2007–2008, 2009–2010, and 2017–2018 from the National Health and Nutrition Examination Survey (NHANES) database.

Methods

This study employed a cross-sectional design and used data from three cycles of the continuous NHANES: 2007–2008, 2009–2010, and 2017–2018. NHANES researchers collected data related to consumption of various food and beverages from participants by employing 24-h dietary recall questionnaires. CKD is defined as an estimated glomerular filtration rate of < 60 mL/min/1.73m2 or a urine albumin-to-creatinine ratio of ≥ 30 mg/g.

Results

The odds ratios (OR) for CKD risk in the second (Q2), third (Q3), and fourth (Q4) quartiles of total flavonoid intake, compared with that in the first (Q1) quartile, were 0.780 (95% CI: 0.600, 1.015), 0.741 (95% CI: 0.573, 0.957), and 0.716 (95% CI: 0.554, 0.925), respectively (with a P value for the trend of 0.040). According to the restricted cubic spline analysis, total flavonoid intake exhibited a non-linear relationship with CKD risk (P < 0.001).

Conclusion

Our findings suggest that a potential J-shaped relationship was observed between total flavonoid consumption and CKD risk, with an inflection point at 69.58 mg/d. Our study indicates that a moderate intake of flavonoids may confer renal benefits which may offer novel strategies for CKD treatment.

Citation: Liu P, Peng W, Hu F, Li G (2024) Association between dietary intake of flavonoid and chronic kidney disease in US adults: Evidence from NHANES 2007-2008, 2009-2010, and 2017-2018. PLoS ONE 19(8): e0309026. https://doi.org/10.1371/journal.pone.0309026

Editor: Tauqeer Hussain Mallhi, Al-Jouf University College of Pharmacy, SAUDI ARABIA

Received: April 15, 2024; Accepted: July 29, 2024; Published: August 27, 2024

Copyright: © 2024 Liu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: The data relevant to this study are from the National Health and Nutrition Examination Survey (NHANES). NHANES data is publicly available and can be accessed at https://www.cdc.gov/nchs/nhanes. The authors confirm they did not have any special access privileges that others would not have and others would be able to access these data in the same manner as the authors.

Funding: This work was supported by the Project funded by Shenzhen Third People's Hospital (No. G2022030) and the Shenzhen Science and Technology Planning Project (No. JCYJ20220530163003007). Guixia Li (corresponding author) is responsible for the project funded by Shenzhen Third People's Hospital (No. G2022030), and Wujian Peng (co-first author) is responsible for the Shenzhen Science and Technology Planning Project (No. JCYJ20220530163003007). The contributions of the authors are as follows: • Wujian Peng: Data curation, Formal analysis, Investigation, Methodology, Software, Writing - Review & Editing. • Guixia Li: Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Writing - Review & Editing.

Competing interests: The authors have declared that no competing interests exist.

Introduction

Chronic kidney disease (CKD) is a global public health challenge, prompting urgent widespread attention worldwide. According to data from the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), approximately 700 million individuals globally are afflicted by CKD, and this number continues to increase steadily [1]. The CKD burden encompasses a spectrum of health and economic problems, including cardiovascular complications, renal failure, increased healthcare expenditures, diminished quality of life, socioeconomic disparities, and societal repercussions [2, 3]. Consequently, offering timely and efficacious intervention for CKD is extremely crucial. During CKD management, interventions targeting risk factors, including blood pressure, blood glucose, and uric acid levels, and dietary interventions, such as restricting protein, purine, salt, and potassium intake, are both indispensable [4]. Although these interventions offer some renal benefits to CKD patients, effective treatments are lacking.

Flavonoids are naturally occurring polyphenolic compounds found in plants. Structurally, they include aromatic rings, hydrophilic groups, and unsaturated bonds, and are subcategorized into flavones, flavonols, flavanones, isoflavones, flavan-3-ols, and anthocyanins [5–8]. Some studies have reported that high flavonoid consumption is negatively associated with cardiovascular diseases, metabolic syndrome, non-alcoholic fatty liver disease, liver fibrosis, high uric acid levels, tumors, and cognitive impairment [9–15]. This may be attributable to the biological activities of flavonoid-rich foods, such as reduction in oxidative damage, attenuation of inflammatory responses, antifibrotic effects, immunomodulation, and enhancement of cytokine secretion [5, 16–19]. Some clinical studies have also indicated the potential benefits of flavonoid-rich foods in CKD patients. A correlation study demonstrated that a high intake of flavonoid-rich foods is associated with a reduced incidence of diabetic nephropathy [20]. In a randomized double-blind trial conducted among end-stage kidney disease patients, excessive daily intake of flavanols, a type of flavonoid, improved vascular endothelial function [21]. Furthermore, renal benefits associated with flavonoid-rich foods may be a result of the collective interaction of multiple mechanisms. These signaling pathways can ameliorate glomerular hyperfiltration, decrease proteinuria, exert antioxidant effects, reduce the expression of inflammatory factors, and safeguard endothelial cells, ultimately contributing to the improvement in renal function [6, 22–26]. Despite the potential renal benefits conferred on CKD patients through the consumption of flavonoid-rich foods, large-scale population studies investigating the relationship between flavonoid consumption and CKD are lacking. Consequently, a significant research remains imperative in investigating the interplay of flavonoid intake and CKD within a broader population context.

The National Health and Nutrition Examination Survey (NHANES) database is operated by the National Center for Health Statistics (NCHS) in the US. It is a national-level health and nutrition survey project that assesses health, nutrition, and prevalence of chronic diseases among US population. We here explored the association between flavonoid consumption and CKD by using cross-sectional data from the NHANES database. Because the biological activities of different flavonoid subtypes potentially vary, we also investigated the relationship between CKD and flavonoid subgroups.

Materials and methods

Study design and study population

The NHANES database is a publicly accessible repository of data of study participants recruited biennially by using a complex multi-stage stratified sampling design. The repository includes demographic, questionnaire, dietary, physical examination, and laboratory examination data. After these data are subjected to weighting procedures, they can effectively represent the entire US population [27].

Weighting is a crucial step in the analysis of NHANES data. It involves adjusting the data to account for the survey’s complex sampling design, including oversampling of certain populations, survey non-responses, and post-stratification to match the US population demographics. This process ensures that the results can be generalized to the entire US population. The weighting factor provided by NHANES is applied to each participant to make the sample representative of the broader population.

This study employed a cross-sectional design and used data from three cycles of the continuous NHANES: 2007–2008, 2009–2010, and 2017–2018. After applying these weights, the results of this study are representative of 306,640,845 US residents. Following the exclusion of individuals under the age of 20 and those with missing data, a total of 23,259,068 participants were selected.

Each participant in NHANES provided written informed consent, and survey data collection was approved by the Research Ethics Review Board of the NCHS. The data used for these analyses were fully de-identified and made publicly available, and thus were exempted from the review of our institutional ethics review board.

Dietary flavonoid intake

The total flavonoid intake from food was calculated using a complex methodology. In 2007–2010 and 2017–2018, NHANES researchers collected data related to consumption of various food and beverages from participants by employing 24-h dietary recall questionnaires. These data covered flavonoid-rich foods and beverages rich, such as onions, celery, tea, and red wine. Subsequently, food codes of Food and Nutrient Database for Dietary Studies (FNDDS) were used to match flavonoid-containing foods and acquire their respective flavonoid content. Specifically, FNDDS version 4.1 food codes were used for the NHANES 2007–2008 data, while FNDDS version 5.0 food codes were used for the NHANES 2009–2010 and 2017–2018 data [14, 28]. Daily flavonoid intake is calculated as the sum of the flavonoid content from various foods. We computed the daily flavonoid intake as the average of flavonoid intake over 2 days to provide a more specific reflection of individuals’ dietary habits. Of note, the Automated Multiple-Pass Method (AMPM) utilized in the questionnaire survey has undergone comprehensive validation in numerous research studies, establishing it as a dependable approach for evaluating both group energy intake and adult sodium intake [29, 30]. Furthermore, the NHANES database provides the daily intake data of six flavonoid subgroups, namely anthocyanins, flavan-3-ols, flavanones, flavones, flavonols, and isoflavones, to facilitate a comprehensive understanding of flavonoid compounds [12, 14, 20, 31].

Study outcomes

A solid-phase fluorescent immunoassay was conducted for measuring human urinary albumin levels [32]. The Jaffe rate method was employed to determine serum and urine creatinine concentrations. The estimated glomerular filtration rate (eGFR) was calculated using the 2012 CKD-EPI equation, which is based on serum creatinine levels [33]. According to the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines, CKD was defined as an eGFR < 60 ml/min/1.73 m2 and/or a urinary albumin-to-creatinine ratio (uACR) ≥ 30 mg/g [4]. An eGFR < 60 ml/min/1.73 m2 indicated a decline in eGFR, while a uACR ≥ 30 mg/g indicated proteinuria. Our primary objective was to investigate the relationship between dietary flavonoid intake and the risk of CKD in U.S. adults. The secondary endpoints were the relationships between dietary flavonoid intake and the risks of eGFR decline and proteinuria, respectively.

Covariates

The following covariates were incorporated in this study: sex (male vs. female), age, race (Black, White, Mexican, others), education level (high school or above vs. middle school or below), height, weight, body mass index (BMI), diastolic blood pressure (DBP), systolic blood pressure (SBP), poverty income ratio (PIR), smoking status (former, never, or now), and presence of chronic diseases including hypertension, hyperlipidemia, hyperuricemia, and diabetes. Energy intake refers to the daily calorie intake (kcal). Physical activity was evaluated in terms of metabolic equivalent of task (MET) minutes per week and categorized into two groups based on whether it exceeded 600 MET minutes per week [34]. BMI is calculated by dividing weight (in kilograms) by the square of height (in meters). PIR is transformed into a binary variable with a cut-off point set at 1. Blood pressure data were based on the average of three measurements. Hypertension was defined as SBP > 140 mmHg, DBP > 90 mmHg, use of antihypertensive medications, or a physician made clinical diagnosis of hypertension [35]. Dyslipidemia is defined as hypertriglyceridemia ≥ 150 mg/dL, total cholesterol ≥ 200 mg/dL, low-density lipoprotein cholesterol (LDL) ≥ 130 mg/dL, high-density lipoprotein (HDL) cholesterol < 40 mg/dL in men, HDL < 50 mg/dL in females, use of lipid-lowering medications, or a physician made diagnosis of hyperlipidemia [36]. Diabetes is defined as glycated hemoglobin > 6.5%, fasting blood glucose > 7.0 mmol/L, random blood glucose > 11.1 mmol/L, 2-h oral glucose tolerance test blood glucose > 11.1mmol/L, use of antidiabetics, or a physician made clinical diagnosis of diabetes [37]. Hyperuricemia is defined as serum uric acid levels >420 μmol/L in men or >360 μmol/L in women [38].

Statistical methods

NHANES data were obtained through a multistage stratified sampling process. Therefore, all data were weighted before data analysis to represent the entire US population. Continuous variables were presented using means and 95% confidence intervals (95% CIs), and statistical differences between the CKD and non-CKD groups for these variables were assessed using the rank-sum test. On the other hand, categorical variables were expressed as percentages with 95% CI and were compared using the chi-square test. Flavonoid intake was categorized into four quartiles: Q1, Q2, Q3, and Q4. We here explored the relationship between CKD and flavonoid intake through logistic regression. Based on the differences between the CKD and non-CKD groups and clinical experience, age, sex, BMI, ethnicity, education level, drinking status, smoking status, hyperuricemia, hyperlipidemia, hypertension, and diabetes mellitus were selected as covariates in the weighted logistic model. A restricted cubic spline (RCS) was employed for assessing the non-linear relationship between flavonoid intake and CKD risk. Furthermore, relationship between dietary flavonoid consumption and CKD were investigated across subgroup analyses, with interaction tests. Finally, logistic regression models were used to examine the relationship between CKD and different flavonoid subclasses. A P < 0.05 (two-sided) significance level was used to indicate statistical significance. All statistical analyses were conducted using R version 4.3.0 (R Development Core Team, University of Auckland, Auckland City, NZ).

Results

Characteristics of the population

The NHANES data is weighted to account for the complex survey design, non-response, and post-stratification adjustments. This ensures that the findings are representative of the total US population. Post-weighting, the data in this study represented 213,259,068 US adults aged 20 years and above, with 30,889,883 (14.5%) diagnosed with CKD, as shown in Fig 1. The two groups exhibited statistically significant differences in age, sex, ethnicity, height, weight, BMI, SBP, DBP, energy intake, physical smoking status, and prevalence of chronic conditions. Additionally, the intake levels of isoflavones and flavones, eGFR, and uACR differed. Compared with the non-CKD group, the CKD group exhibited older age; higher proportion of women; greater height, weight and BMI; higher SBP; lower DBP; higher prevalence of hyperlipidemia, hypertension, diabetes, and hyperuricemia; and lower daily intake of isoflavones and flavones. Table 1 presents the other results.

thumbnail
Download:
Fig 1. Flowchart of participants selection.

CKD, chronic kidney disease.

https://doi.org/10.1371/journal.pone.0309026.g001

thumbnail
Download:
Table 1. Characteristics of study in US population.

https://doi.org/10.1371/journal.pone.0309026.t001

Association between dietary flavonoid intake and CKD

After adjusting for variables including age, sex, body mass index, ethnicity, smoke status, energy intake, physical activity status, hyperuricemia, hyperlipidemia, hypertension, and diabetes mellitus (Table 2), the odds ratios (ORs) for CKD risk in the Q2, Q3, and Q4 groups of total flavonoid intake, compared with that for CKD incidence in the Q1 group, were 0.780 (95% CI: 0.600, 1.015), 0.741 (95% CI: 0.573, 0.957), and 0.716 (95% CI: 0.554, 0.925), respectively. The P value for the trend test was 0.040.

thumbnail
Download:
Table 2. Association between dietary flavonoid intake and chronic kidney disease in US population.

https://doi.org/10.1371/journal.pone.0309026.t002

According to the RCS analysis shown in Fig 2, total flavonoid intake exhibited a non-linear relationship with CKD risk (P < 0.001). After multivariate calibration (Table 3), the ORs for decreased eGFR risk in the Q2, Q3, and Q4 groups of total flavonoid intake, compared with that for decreased eGFR incidence in the Q1 group, were 0.529 (95% CI: 0.341, 0.821), 0.354 (95% CI: 0.237, 0.529), and 0.533 (95% CI: 0.329, 0.863), respectively. The P value for the trend test was 0.046. In contrast, there is no significant association between flavonoid intake and the risk of elevated uACR.

thumbnail
Download:
Fig 2. The non-linear trend between the intake of flavonoids and the risk of CKD using a restricted cubic spline.

Data are presented as odds ratios of CKD (y-axis) and level of flavonoids (mg/d) after adjusted for age, sex, body mass index, ethnicity, smoke status, energy intake, physical activity status, hyperuricemia, hyperlipidemia, hypertension, and diabetes. RCS, restricted cubic spline; CKD, chronic kidney disease.

https://doi.org/10.1371/journal.pone.0309026.g002

thumbnail
Download:
Table 3. Association between dietary flavonoid and decreased eGFR/increased uACR in the US population.

https://doi.org/10.1371/journal.pone.0309026.t003

Examining the relationship between dietary flavonoid consumption and CKD through subgroup analyses

Table 4 presents the results of our analysis of the association between dietary flavonoid intake and CKD within stratified groups based on sex, age, race, BMI, educational level, smoking status, hypertension, diabetes, hyperlipidemia, and hyperuricemia. Following multivariate adjustment, the ORs (95% CI) for CKD incidence in Q4 compared with Q1 were 0.571 (0.403, 0.811) for women, 0.674 (0.467, 0.973) for participants more than 65 years old, 0.660 (0.490, 0.888) for Caucasians, 0.531 (0.337, 0.837) for participants with a BMI of <25 kg/m2, 0.731 (0.556, 0.960) for participants with hyperlipidemia, 0.576 (0.399, 0.830) for participants with hypertension, and 0.692 (0.503, 0.953) for participants without diabetes. Among these subgroups, all trend tests yielded P-values ≥0.05, except for women, Caucasians, participants with a BMI less than 25 kg/m2, those with hypertension, and those without diabetes. Interaction tests within these subgroups also exhibited P > 0.05.

thumbnail
Download:
Table 4. Stratified analyses by potential modifiers of the association between dietary flavonoid intake and chronic kidney disease in US population.

https://doi.org/10.1371/journal.pone.0309026.t004

Relationship between intakes of six flavonoid subclasses and CKD

Following multivariate adjustment, compared with the Q1 group, ORs (95% CI) for CKD risk in the flavonol subgroup were for 0.701 (0.518, 0.947) for Q3 and 0.642 (0.494, 0.835) for Q4, with a P value for trend of 0.007. Table 5 presents other results. Fig 3 illustrated the nonlinear trend between the intake of six flavonoid subclasses and the CKD risk.

thumbnail
Download:
Fig 3. Utilizing restricted cubic splines to analyze the nonlinear trends between the intake of six flavonoid subclasses and the CKD risk.

CKD, chronic kidney disease.

https://doi.org/10.1371/journal.pone.0309026.g003

thumbnail
Download:
Table 5. Relationship between the intakes of six flavonoid subclasses and chronic kidney disease in US adults.

https://doi.org/10.1371/journal.pone.0309026.t005

Discussion

Based on our analysis of data from NHANES 2007–2010 and 2017–2018, high total flavonoid intake was negatively correlated to CKD risk. Our RCS analysis indicated that a daily flavonoid intake of > 69.58 mg is associated with a reduced risk of CKD. However, no significant relationship was observed between higher daily flavonoid intake and reduced CKD risk. Overall, there is a J-shaped relationship between daily flavonoid intake and reduced CKD risk. The P-values from the interaction tests for each subgroup were all greater than 0.05, indicating the robustness of the study findings across all subgroups. In the flavonoid subgroup analysis, we found that the intake of flavanols may play a key role in renal benefits.

Although flavonoids are commonly present in dietary sources and herbal plants, clinical investigations into the relationship between flavonoid and CKD remain relatively scarce. Soy protein containing isoflavones significantly reduces serum creatinine, serum phosphate, urinary protein, and C-reactive protein levels in non-dialysis CKD patients [39]. A statistically significant trend was noted fin the trend analysis, but daily isoflavones intake was not significantly associated with CKD incidence. This is a cross-sectional study and does not establish a causal relationship between isoflavones and CKD. Furthermore, isoflavones in the present study were derived from soy and other sources. In a randomized controlled trial (RCT), Rassaf et al. demonstrated that daily consumption of cocoa flavanols can improve the vascular endothelial function in patients with end-stage renal disease [21]. Conversely, a CKD population using sodium nitrite and quercetin (a type of flavanol) in Chen and colleagues’ research did not yield vascular endothelial benefits [40]. These two studies differed in terms of their study populations, flavanol sources, flavanol dosages, and methods used for evaluating the vascular endothelial function. The present study did not investigate whether flavanol intake could confer vascular benefits to CKD patients. Subgroup analysis in this study revealed that high flavanols intake was significantly and inversely correlated with CKD incidence, with a trend test P value of 0.05. This association may be attributed to the vascular endothelial protective, anti-inflammatory, and antioxidant functions inherent in flavonol [41–45]. However, flavanols consumed by the study population primarily originated from everyday foods and beverages, daily flavanol intake was relatively modest. Therefore, whether additional intake of higher doses of flavanols can effectively reduce CKD risk remains unclear. Using data from the NHANES database, Liu et al. discovered that daily high flavonoid intake was negatively correlated with the risk of diabetic nephropathy [20]. However, we observed no significant relationship between flavonoid intake and CKD within the subgroup of diabetic patients. Differences in the study populations and endpoint events were observed between the two studies. Liu et al.’s study did not diagnose diabetes on the basis of fasting blood glucose and postprandial blood glucose levels, but they used only uACR for the diagnosis of diabetic nephropathy, which may have introduced biases into the study results. Notably, the consumption of flavonoid-rich substances may cause renal function impairment, which is characterized by acute interstitial nephritis and acute tubular necrosis in clinical case reports [46, 47]. Overall, the potential renal benefits of flavonoid consumption in CKD populations remain debatable.

Many basic studies have explored the relationship between flavonoid compounds such as quercetin, silymarin, epimedium, chrysin, and anthocyanins and CKD. Quercetin, a flavonol type, inhibits apoptosis in renal glomerular endothelial cells through the endoplasmic reticulum stress pathway [22]. Furthermore, quercetin possesses anti-inflammatory and antifibrotic effects. It reduces uremic toxin production through the gastrointestinal tract [45, 48, 49]. Flavonoid compounds such as epimedium, chrysin, and anthocyanins may enhance kidney function in CKD patients through anti-inflammatory and antifibrotic mechanisms [23, 25, 50–53]. Of note, flavonoid compound intake might exhibit a dose-dependent relationship with potential benefits for CKD [52, 53]. Similar to quercetin, rutin, another flavanol, demonstrated no renal benefits [54]. Peng et al. found that flavonoid-rich green tea inhibited the clearance of uremia toxins in chronic renal failure mice and elevated the serum creatinine and urea nitrogen concentrations [55]. Silymarin, an isoflavone type, exerted anti-renal fibrotic effects by modulating the transforming growth factor-β signaling pathway in vitro and in vivo [56, 57]. Additionally, subgroup analysis in this study revealed an association between high flavones intake and a reduced risk of CKD. This may be attributed to potential improvements in renal circulation and alleviation of kidney inflammation [58, 59]. In summary, the flavonoid compounds exert beneficial effects on the kidneys through functions such as antioxidation, antifibrosis, anti-apoptosis, anti-inflammation, and reduction of uremic toxins. However, it is possible that various types and sources of flavonoids may exert different effects on the kidneys in individuals with CKD.

To our best understanding, no study has explored the relationship between CKD and daily flavonoid consumption in a large-scale population. We analyzed data from the NHANES survey to examine the association between flavonoid intake, including its subcategories, and CKD prevalence, in the US population and various subgroups.

This study has certain limitations that warrant acknowledgment. First, the definition of CKD involves abnormal kidney function for a duration of >3 months, constituting a chronic process. However, the average flavonoid intake over 2 days may not accurately represent daily dietary habits, potentially introducing bias into the study findings. Second, the study’s participant pool was confined to patients residing in the US, and the relationship between daily flavonoid consumption and CKD among the populations of other countries or regions remains unclear. Third, both flavonoids and their subgroups include various compounds, each with varying biological activities. Consequently, the present study could not specifically elucidate which compound(s) may influence CKD. Fourth, the absence of renal ultrasonography and renal pathological data may have caused an underestimation of CKD incidence, potentially resulting in a bias in the study findings. Fifth, some confounding factors may not have been considered, which could lead to bias. Finally, the excessive daily intake of flavan-3-ols may potentially affect the biological effects of other flavonoid subgroups.

Conclusions

On analyzing data from NHANES 2007–2008, 2009–2010 and 2017–2018, a potential J-shaped relationship was observed between total flavonoid consumption and CKD risk, with an inflection point at 69.58 mg/d. Our study indicates that a moderate intake of flavonoids may confer renal benefits which may offer novel strategies for CKD treatment.

Acknowledgments

The authors are grateful to the National Health and Nutrition Examination Survey (NHANES) team for providing the data.

References

  1. 1. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet (London, England). 2020;395(10225):709–33. Epub 2020/02/18. pmid:32061315
  2. 2. Cockwell P, Fisher LA. The global burden of chronic kidney disease. Lancet (London, England). 2020;395(10225):662–4. Epub 2020/02/18. pmid:32061314.
  3. 3. Carney EF. The impact of chronic kidney disease on global health. Nature reviews Nephrology. 2020;16(5):251. Epub 2020/03/08. pmid:32144399.
  4. 4. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014;63(5):713–35. Epub 2014/03/22. pmid:24647050.
  5. 5. Shen N, Wang T, Gan Q, Liu S, Wang L, Jin B. Plant flavonoids: Classification, distribution, biosynthesis, and antioxidant activity. Food Chem. 2022;383:132531. Epub 2022/04/14. pmid:35413752.
  6. 6. Vargas F, Romecín P, García-Guillén AI, Wangesteen R, Vargas-Tendero P, Paredes MD, et al. Flavonoids in Kidney Health and Disease. Frontiers in physiology. 2018;9:394. Epub 2018/05/10. pmid:29740333
  7. 7. Khan J, Deb PK, Priya S, Medina KD, Devi R, Walode SG, et al. Dietary Flavonoids: Cardioprotective Potential with Antioxidant Effects and Their Pharmacokinetic, Toxicological and Therapeutic Concerns. Molecules. 2021;26(13). Epub 2021/07/03. pmid:34209338
  8. 8. Rudrapal M, Khan J, Dukhyil AAB, Alarousy R, Attah EI, Sharma T, et al. Chalcone Scaffolds, Bioprecursors of Flavonoids: Chemistry, Bioactivities, and Pharmacokinetics. Molecules. 2021;26(23). Epub 2021/12/11. pmid:34885754
  9. 9. Yeh TS, Yuan C, Ascherio A, Rosner BA, Willett WC, Blacker D. Long-term Dietary Flavonoid Intake and Subjective Cognitive Decline in US Men and Women. Neurology. 2021;97(10):e1041–e56. Epub 2021/07/30. pmid:34321362
  10. 10. Sebastian RS, Fanelli Kuczmarski MT, Goldman JD, Moshfegh AJ, Zonderman AB, Evans MK. Usual Intake of Flavonoids Is Inversely Associated with Metabolic Syndrome in African American and White Males but Not Females in Baltimore City, Maryland, USA. Nutrients. 2022;14(9). Epub 2022/05/15. pmid:35565891
  11. 11. Tong J, Zeng Y, Xie J, Xiao K, Li M, Cong L. Association between flavonoid and subclasses intake and metabolic associated fatty liver disease in U.S. adults: Results from National Health and Nutrition Examination Survey 2017–2018. Front Nutr. 2022;9:1074494. Epub 2022/12/20. pmid:36532560
  12. 12. Li H, Shi L, Chen X, Wang M. Association between dietary intake of flavonoids and hyperuricemia: a cross-sectional study. BMC public health. 2023;23(1):1227. Epub 2023/06/25. pmid:37355562
  13. 13. Xie R, Zhang Y. Associations between dietary flavonoid intake with hepatic steatosis and fibrosis quantified by VCTE: Evidence from NHANES and FNDDS. Nutrition, metabolism, and cardiovascular diseases: NMCD. 2023;33(6):1179–89. Epub 2023/03/25. pmid:36964061.
  14. 14. Zhao Z, Gao W, Ding X, Xu X, Xiao C, Mao G, et al. The association between dietary intake of flavonoids and its subclasses and the risk of metabolic syndrome. Front Nutr. 2023;10:1195107. Epub 2023/07/21. pmid:37476404
  15. 15. Liu F, Peng Y, Qiao Y, Huang Y, Song F, Zhang M, et al. Consumption of flavonoids and risk of hormone-related cancers: a systematic review and meta-analysis of observational studies. Nutr J. 2022;21(1):27. Epub 2022/05/12. pmid:35545772
  16. 16. Serafini M, Peluso I, Raguzzini A. Flavonoids as anti-inflammatory agents. Proc Nutr Soc. 2010;69(3):273–8. Epub 2010/06/24. pmid:20569521.
  17. 17. Wen K, Fang X, Yang J, Yao Y, Nandakumar KS, Salem ML, et al. Recent Research on Flavonoids and their Biomedical Applications. Curr Med Chem. 2021;28(5):1042–66. Epub 2020/07/15. pmid:32660393.
  18. 18. Slika H, Mansour H, Wehbe N, Nasser SA, Iratni R, Nasrallah G, et al. Therapeutic potential of flavonoids in cancer: ROS-mediated mechanisms. Biomed Pharmacother. 2022;146:112442. Epub 2022/01/23. pmid:35062053.
  19. 19. Wen L, Jiang Y, Yang J, Zhao Y, Tian M, Yang B. Structure, bioactivity, and synthesis of methylated flavonoids. Ann N Y Acad Sci. 2017;1398(1):120–9. Epub 2017/04/25. pmid:28436044.
  20. 20. Liu F, Nie J, Deng MG, Yang H, Feng Q, Yang Y, et al. Dietary flavonoid intake is associated with a lower risk of diabetic nephropathy in US adults: data from NHANES 2007–2008, 2009–2010, and 2017–2018. Food Funct. 2023;14(9):4183–90. Epub 2023/04/18. pmid:37066968.
  21. 21. Rassaf T, Rammos C, Hendgen-Cotta UB, Heiss C, Kleophas W, Dellanna F, et al. Vasculoprotective Effects of Dietary Cocoa Flavanols in Patients on Hemodialysis: A Double-Blind, Randomized, Placebo-Controlled Trial. Clinical journal of the American Society of Nephrology: CJASN. 2016;11(1):108–18. Epub 2015/12/19. pmid:26681132
  22. 22. Guo W, Ding J, Zhang A, Dai W, Liu S, Diao Z, et al. The inhibitory effect of quercetin on asymmetric dimethylarginine-induced apoptosis is mediated by the endoplasmic reticulum stress pathway in glomerular endothelial cells. International journal of molecular sciences. 2014;15(1):484–503. Epub 2014/01/24. pmid:24451129
  23. 23. Ali BH, Adham SA, Al Za’abi M, Waly MI, Yasin J, Nemmar A, et al. Ameliorative effect of chrysin on adenine-induced chronic kidney disease in rats. PloS one. 2015;10(4):e0125285. Epub 2015/04/25. pmid:25909514
  24. 24. Miao H, Wu XQ, Wang YN, Chen DQ, Chen L, Vaziri ND, et al. 1-Hydroxypyrene mediates renal fibrosis through aryl hydrocarbon receptor signalling pathway. Br J Pharmacol. 2022;179(1):103–24. Epub 2021/10/10. pmid:34625952.
  25. 25. Zhao Y, Zhang R, Mu L, Yang W, Zhang X, Han L, et al. Total flavonoids in Epimedium koreanum Nakai alleviated chronic renal failure via promoting AMPK activation. Food Funct. 2022;13(2):904–19. Epub 2022/01/08. pmid:34994765.
  26. 26. Ju HY, Kim J, Han SJ. The flavonoid fisetin ameliorates renal fibrosis by inhibiting SMAD3 phosphorylation, oxidative damage, and inflammation in ureteral obstructed kidney in mice. Kidney research and clinical practice. 2023;42(3):325–39. Epub 2023/04/26. pmid:37098680
  27. 27. Zipf G, Chiappa M, Porter KS, Ostchega Y, Lewis BG, Dostal J. National health and nutrition examination survey: plan and operations, 1999–2010. Vital Health Stat 1. 2013;(56):1–37. Epub 2014/08/01. pmid:25078429.
  28. 28. Sebastian RS, Wilkinson Enns C, Goldman JD, Martin CL, Steinfeldt LC, Murayi T, et al. A New Database Facilitates Characterization of Flavonoid Intake, Sources, and Positive Associations with Diet Quality among US Adults. J Nutr. 2015;145(6):1239–48. Epub 2015/05/08. pmid:25948787
  29. 29. Moshfegh AJ, Rhodes DG, Baer DJ, Murayi T, Clemens JC, Rumpler WV, et al. The US Department of Agriculture Automated Multiple-Pass Method reduces bias in the collection of energy intakes. Am J Clin Nutr. 2008;88(2):324–32. Epub 2008/08/12. pmid:18689367.
  30. 30. Rhodes DG, Murayi T, Clemens JC, Baer DJ, Sebastian RS, Moshfegh AJ. The USDA Automated Multiple-Pass Method accurately assesses population sodium intakes. Am J Clin Nutr. 2013;97(5):958–64. Epub 2013/04/05. pmid:23553153.
  31. 31. Chen WL, Zhao J. Association between dietary anthocyanidins intake and depression among US adults: a cross-sectional study (NHANES, 2007–2010 and 2017–2018). BMC Psychiatry. 2023;23(1):525. Epub 2023/07/21. pmid:37474898
  32. 32. Chavers BM, Simonson J, Michael AF. A solid phase fluorescent immunoassay for the measurement of human urinary albumin. Kidney Int. 1984;25(3):576–8. Epub 1984/03/01. pmid:6737844.
  33. 33. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. The New England journal of medicine. 2012;367(1):20–9. pmid:22762315.
  34. 34. Vilar-Gomez E, Nephew LD, Vuppalanchi R, Gawrieh S, Mladenovic A, Pike F, et al. High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population. Hepatology. 2022;75(6):1491–506. Epub 2021/10/21. pmid:34668597.
  35. 35. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet (London, England). 2007;370(9587):591–603. Epub 2007/08/21. pmid:17707755.
  36. 36. Arvanitis M, Lowenstein CJ. Dyslipidemia. Ann Intern Med. 2023;176(6):Itc81–itc96. Epub 2023/06/12. pmid:37307585.
  37. 37. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S15–s33. Epub 2020/12/11. pmid:33298413.
  38. 38. Joosten LAB, Crişan TO, Bjornstad P, Johnson RJ. Asymptomatic hyperuricaemia: a silent activator of the innate immune system. Nature reviews Rheumatology. 2020;16(2):75–86. Epub 2019/12/12. pmid:31822862
  39. 39. Jing Z, Wei-Jie Y. Effects of soy protein containing isoflavones in patients with chronic kidney disease: A systematic review and meta-analysis. Clinical nutrition (Edinburgh, Scotland). 2016;35(1):117–24. Epub 2015/04/18. pmid:25882339.
  40. 40. Chen J, Hamm LL, Bundy JD, Kumbala DR, Bodana S, Chandra S, et al. Combination Treatment with Sodium Nitrite and Isoquercetin on Endothelial Dysfunction among Patients with CKD: A Randomized Phase 2 Pilot Trial. Clinical journal of the American Society of Nephrology: CJASN. 2020;15(11):1566–75. Epub 2020/10/08. pmid:33023894
  41. 41. Balzer J, Rassaf T, Heiss C, Kleinbongard P, Lauer T, Merx M, et al. Sustained benefits in vascular function through flavanol-containing cocoa in medicated diabetic patients a double-masked, randomized, controlled trial. Journal of the American College of Cardiology. 2008;51(22):2141–9. Epub 2008/05/31. pmid:18510961.
  42. 42. Sansone R, Rodriguez-Mateos A, Heuel J, Falk D, Schuler D, Wagstaff R, et al. Cocoa flavanol intake improves endothelial function and Framingham Risk Score in healthy men and women: a randomised, controlled, double-masked trial: the Flaviola Health Study. Br J Nutr. 2015;114(8):1246–55. Epub 2015/09/09. pmid:26348767
  43. 43. Rodriguez-Mateos A, Hezel M, Aydin H, Kelm M, Lundberg JO, Weitzberg E, et al. Interactions between cocoa flavanols and inorganic nitrate: additive effects on endothelial function at achievable dietary amounts. Free Radic Biol Med. 2015;80:121–8. Epub 2014/12/23. pmid:25530151.
  44. 44. Widowati W, Prahastuti S, Tjokropranoto R, Onggowidjaja P, Kusuma HSW, Afifah E, et al. Quercetin prevents chronic kidney disease on mesangial cells model by regulating inflammation, oxidative stress, and TGF-β1/SMADs pathway. PeerJ. 2022;10:e13257. Epub 2022/06/09. pmid:35673387
  45. 45. Guo S, Sun J, Zhuang Y. Quercetin alleviates lipopolysaccharide-induced inflammatory responses by up-regulation miR-124 in human renal tubular epithelial cell line HK-2. Biofactors. 2020;46(3):402–10. Epub 2019/12/06. pmid:31804760.
  46. 46. Lin JL, Ho YS. Flavonoid-induced acute nephropathy. Am J Kidney Dis. 1994;23(3):433–40. Epub 1994/03/01. pmid:8128947
  47. 47. Lee JJ, Chen HC. Flavonoid-induced acute nephropathy by Cupressus funebris Endl (Mourning Cypress). Am J Kidney Dis. 2006;48(5):e81–5. Epub 2006/10/25. pmid:17059987.
  48. 48. Chen YQ, Chen HY, Tang QQ, Li YF, Liu XS, Lu FH, et al. Protective effect of quercetin on kidney diseases: From chemistry to herbal medicines. Frontiers in pharmacology. 2022;13:968226. Epub 2022/09/20. pmid:36120321
  49. 49. Ren Q, Cheng L, Guo F, Tao S, Zhang C, Ma L, et al. Fisetin Improves Hyperuricemia-Induced Chronic Kidney Disease via Regulating Gut Microbiota-Mediated Tryptophan Metabolism and Aryl Hydrocarbon Receptor Activation. J Agric Food Chem. 2021;69(37):10932–42. Epub 2021/09/11. pmid:34505780.
  50. 50. Chen HA, Chen CM, Guan SS, Chiang CK, Wu CT, Liu SH. The antifibrotic and anti-inflammatory effects of icariin on the kidney in a unilateral ureteral obstruction mouse model. Phytomedicine. 2019;59:152917. Epub 2019/04/13. pmid:30978648.
  51. 51. Wang M, Wang L, Zhou Y, Feng X, Ye C, Wang C. Icariin attenuates renal fibrosis in chronic kidney disease by inhibiting interleukin-1β/transforming growth factor-β-mediated activation of renal fibroblasts. Phytother Res. 2021;35(11):6204–15. Epub 2021/08/25. pmid:34426999.
  52. 52. Kanlaya R, Thongboonkerd V. Protective Effects of Epigallocatechin-3-Gallate from Green Tea in Various Kidney Diseases. Adv Nutr. 2019;10(1):112–21. Epub 2019/01/08. pmid:30615092
  53. 53. Ali BH, Cahliková L, Opletal L, Karaca T, Manoj P, Ramkumar A, et al. Effect of aqueous extract and anthocyanins of calyces of Hibiscus sabdariffa (Malvaceae) in rats with adenine-induced chronic kidney disease. J Pharm Pharmacol. 2017;69(9):1219–29. Epub 2017/05/26. pmid:28542915.
  54. 54. Hsieh CL, Peng CC, Chen KC, Peng RY. Rutin (quercetin rutinoside) induced protein-energy malnutrition in chronic kidney disease, but quercetin acted beneficially. J Agric Food Chem. 2013;61(30):7258–67. Epub 2013/07/24. pmid:23876017.
  55. 55. Peng YH, Sweet DH, Lin SP, Yu CP, Lee Chao PD, Hou YC. Green tea inhibited the elimination of nephro-cardiovascular toxins and deteriorated the renal function in rats with renal failure. Sci Rep. 2015;5:16226. Epub 2015/11/11. pmid:26552961
  56. 56. Liu R, Wang Q, Ding Z, Zhang X, Li Y, Zang Y, et al. Silibinin Augments the Antifibrotic Effect of Valsartan Through Inactivation of TGF-β1 Signaling in Kidney. Drug Des Devel Ther. 2020;14:603–11. Epub 2020/02/28. pmid:32103902
  57. 57. Ma Z, Zang W, Wang H, Wei X. Silibinin enhances anti-renal fibrosis effect of MK-521 via downregulation of TGF-β signaling pathway. Hum Cell. 2020;33(2):330–6. Epub 2020/01/19. pmid:31953678.
  58. 58. Li F, Wei R, Huang M, Chen J, Li P, Ma Y, et al. Luteolin can ameliorate renal interstitial fibrosis-induced renal anaemia through the SIRT1/FOXO3 pathway. Food Funct. 2022;13(22):11896–914. Epub 2022/11/03. pmid:36321482.
  59. 59. Liu S, Ye L, Tao J, Ge C, Huang L, Yu J. Total flavones of Abelmoschus manihot improve diabetic nephropathy by inhibiting the iRhom2/TACE signalling pathway activity in rats. Pharm Biol. 2017;56(1):1–11. Epub 2017/12/10. pmid:29221422